68Ga-P3 PET/CT Imaging in Prostate
A Study to Evaluate 68Ga-P3 PET/CT Imaging of PSMA Expression in Prostate
Peking University First Hospital
30 participants
May 29, 2023
INTERVENTIONAL
Conditions
Summary
Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that consists of 750 amino acids. It is highly expressed on most prostate cancer cells and neovascular endothelial cells of tumors, making PSMA a highly specific and significant imaging target for malignancies. \[68Ga\]P3, a novel molecular probe of PET imaging agent that targets PSMA, can be used in the diagnosis and research of a wide variety of PSMA high-expression malignanciesr.
Eligibility
Inclusion Criteria1
- patients with confirmed or suspected cancer; Signed written informed consent
Interventions
68Ga-P3 is injected intravenously with a dose of 0.06-0.08 mCi/kg.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05940259